BR112013007287A2 - amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase - Google Patents

amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase

Info

Publication number
BR112013007287A2
BR112013007287A2 BR112013007287A BR112013007287A BR112013007287A2 BR 112013007287 A2 BR112013007287 A2 BR 112013007287A2 BR 112013007287 A BR112013007287 A BR 112013007287A BR 112013007287 A BR112013007287 A BR 112013007287A BR 112013007287 A2 BR112013007287 A2 BR 112013007287A2
Authority
BR
Brazil
Prior art keywords
amides
oxodiazepine
azetine
oxopiperazine
azetidine
Prior art date
Application number
BR112013007287A
Other languages
English (en)
Inventor
Bin Zhu
Mark E Mcdonnell
Mark J Macielag
Peter J Connolly
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112013007287A2 publication Critical patent/BR112013007287A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase. a presente invenção refere-se a compostos, composições e métodos para tratamento de várias doenças, síndromes, condições e distúrbios, incluindo dor. tais compostos e seus enantiômeros, diastereômeros, e sais farmaceuticamente aceitáveis são representados pela fórmula (ia) e fórmula (ib) da seguinte forma: fórmula (ia) em que y,z, e n são aqui definidos, e fórmula (ib) em que y~ b~ e z~ b~ são conforme definidos aqui.
BR112013007287A 2010-09-27 2011-09-27 amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase BR112013007287A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38677710P 2010-09-27 2010-09-27
PCT/US2011/053442 WO2012044613A1 (en) 2010-09-27 2011-09-27 Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
BR112013007287A2 true BR112013007287A2 (pt) 2016-06-14

Family

ID=44906361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007287A BR112013007287A2 (pt) 2010-09-27 2011-09-27 amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase

Country Status (11)

Country Link
US (1) US8637498B2 (pt)
EP (1) EP2621918A1 (pt)
JP (1) JP2013537920A (pt)
KR (1) KR20140001206A (pt)
CN (1) CN103080103A (pt)
AR (1) AR083180A1 (pt)
AU (1) AU2011307252B2 (pt)
BR (1) BR112013007287A2 (pt)
CA (1) CA2810077A1 (pt)
RU (1) RU2013114852A (pt)
WO (1) WO2012044613A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099196A1 (en) 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
EP3197450A1 (en) 2014-09-22 2017-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fibrosis
JP6653319B2 (ja) 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
MX2018000929A (es) 2015-07-31 2018-05-22 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl.
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
US10323026B2 (en) 2016-03-31 2019-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN110382479A (zh) 2017-01-20 2019-10-25 辉瑞大药厂 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
EP3571202B1 (en) 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
MX2020007318A (es) 2017-09-29 2020-08-24 Takeda Pharmaceuticals Co Compuesto heterociclico.
CN110577515B (zh) * 2019-09-02 2022-05-17 南通大学 一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法
CN115124447A (zh) * 2022-08-29 2022-09-30 山东诚创蓝海医药科技有限公司 一种3-氮杂环丁酮盐酸盐的制备方法
CN115417804A (zh) * 2022-09-16 2022-12-02 天津药明康德新药开发有限公司 一种7-甲基-1h-吲哚-5-羧酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6179998A (en) 1997-02-24 1998-09-09 Zymogenetics Inc. Calcitonin mimetics
WO1999019297A1 (en) 1997-10-15 1999-04-22 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
WO2000063168A1 (en) 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JPWO2004002531A1 (ja) 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
WO2004056800A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
PE20071136A1 (es) 2005-12-21 2007-12-29 Schering Corp Derivados de anilina sustituida como antagonistas de la histamina h3
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2915199B1 (fr) 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
US9271962B2 (en) 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
US8257698B2 (en) * 2008-04-25 2012-09-04 Janssen Pharmaceutica N.V. Protein engineering of monoacylglycerol lipase (MGLL)
AU2009240460B2 (en) 2008-04-25 2016-03-17 Janssen Pharmaceutica Nv Crystal structure of monoacylglycerol lipase (MGLL)
US8435977B2 (en) * 2009-04-22 2013-05-07 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
JP2012524805A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
CN102548983B (zh) 2009-04-22 2014-09-17 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺

Also Published As

Publication number Publication date
AU2011307252B2 (en) 2015-06-25
WO2012044613A1 (en) 2012-04-05
US8637498B2 (en) 2014-01-28
CA2810077A1 (en) 2012-04-05
CN103080103A (zh) 2013-05-01
EP2621918A1 (en) 2013-08-07
US20120077797A1 (en) 2012-03-29
AU2011307252A1 (en) 2013-03-14
KR20140001206A (ko) 2014-01-06
AR083180A1 (es) 2013-02-06
JP2013537920A (ja) 2013-10-07
RU2013114852A (ru) 2014-11-10

Similar Documents

Publication Publication Date Title
BR112013007287A2 (pt) amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase
BR112013005141A2 (pt) diazetidinil diamida como inibidores de monoacilglicerol lipase
BR112017006809A2 (pt) compostos de ácido carboxílico úteis para inibir a prostaglandina e2 sintase-1 microssômica
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
BR112012010253A2 (pt) compostos de pirimidina como moduladores do receptor delta opioide
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CO6480975A2 (es) Mimetico de smac
BR112013002957A2 (pt) composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina
PH12015500376A1 (en) Novel bicyclic pyridinones
PH12015500316A1 (en) Substituted pyrazoles as n-type calcium channel blockers
CR20110255A (es) Nuevos compuestos 578
MX345780B (es) Inhibidores triciclicos de girasa.
IN2012DN03182A (pt)
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
BR112015003359A2 (pt) pirrolopirazóis como bloqueadores de canal de cálcio de tipo-n
IN2012DN03846A (pt)
BR112017000584A2 (pt) inibidores da aldosterona sintase
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
PH12015500314A1 (en) Cyclopentylpyrazoles as n-type calcium channel blockers
BR112012007755A2 (pt) profármacos de derivado de piperidinila como moduladores da atividade de receptores de quimiocinas
MX2013005050A (es) Derivados de indol.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.